MLYS · Insider Trading
Mineralys Therapeutics, Inc. Common Stock
Every open-market purchase and sale reported by MLYS officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-20 | Lonnel Coats | Director | A | +12,400 | — |
| 2026-10-20 | Kristine Peterson | Director | A | +12,400 | — |
| 2026-10-02 | Jon Congleton | Chief Executive Officer | Sell | −75,000 | −$1.91M |
| 2026-09-24 | Brian Taylor Slingsby | Director | Sell | −104,320 | −$3.01M |
| 2026-09-22 | Eric Warren | Chief Commercial Officer | MIXED | — | −$110.66K |
| 2026-09-17 | Daphne Karydas | Director | MIXED | — | −$49.68K |
| 2026-08-25 | Eric Warren | Chief Commercial Officer | MIXED | — | −$94.72K |
| 2026-08-12 | David Malcom Rodman | Chief Medical Officer | MIXED | — | −$24.07K |
| 2026-08-12 | James J. Ferguson III | Chief Medical Officer | A | +102,400 | — |
| 2026-07-23 | Eric Warren | Chief Commercial Officer | MIXED | — | −$101.41K |
| 2026-07-20 | David Malcom Rodman | Chief Medical Officer | MIXED | — | −$4.61K |
| 2026-07-15 | Jon Congleton | Chief Executive Officer | Sell | −10,700 | −$291.44K |
| 2026-07-15 | David Malcom Rodman | Chief Medical Officer | MIXED | −6,349 | −$454.31K |
| 2026-07-10 | David Malcom Rodman | Chief Medical Officer | MIXED | — | −$31.05K |
| 2026-06-17 | David Malcom Rodman | Chief Medical Officer | MIXED | −6,348 | −$248.14K |
| 2026-06-17 | Daphne Karydas | Director | MIXED | — | −$38.94K |
| 2026-06-12 | David Malcom Rodman | Chief Medical Officer | MIXED | — | −$164.57K |
| 2026-05-19 | David Malcom Rodman | Chief Medical Officer | MIXED | — | −$5.05K |
| 2026-05-13 | David Malcom Rodman | Chief Medical Officer | MIXED | −6,349 | −$515.56K |
| 2026-04-21 | David Malcom Rodman | Chief Medical Officer | MIXED | — | −$6.61K |
| 2026-04-15 | Jon Congleton | Chief Executive Officer | Sell | −15,730 | −$421.98K |
| 2026-04-15 | David Malcom Rodman | Chief Medical Officer | MIXED | −6,348 | −$446.31K |
| 2026-04-13 | David Malcom Rodman | Chief Medical Officer | MIXED | — | −$24.69K |
| 2026-04-02 | Jon Congleton | Chief Executive Officer | Sell | −75,000 | −$1.97M |
| 2026-04-02 | Daphne Karydas | Director | MIXED | — | −$38.94K |
| 2026-03-17 | David Malcom Rodman | Chief Medical Officer | MIXED | — | −$4.26K |
| 2026-03-16 | David Malcom Rodman | Chief Medical Officer | MIXED | −6,349 | −$440.61K |
| 2026-03-10 | David Malcom Rodman | Chief Medical Officer | MIXED | — | −$23.53K |
| 2026-02-20 | Jon Congleton | Chief Executive Officer | A | +140,900 | — |
| 2026-02-20 | Glenn Sblendorio | Director | A | +6,200 | — |
| 2026-02-20 | David Malcom Rodman | Chief Medical Officer | A | +38,400 | — |
| 2026-02-20 | Srinivas Akkaraju | Director | A | +6,200 | — |
| 2026-02-20 | Daphne Karydas | Director | A | +6,200 | — |
| 2026-02-20 | Adam Scott Levy | CFO and Secretary | A | +39,900 | — |
| 2026-02-20 | Derek DiRocco | Director | A | +6,200 | — |
| 2026-02-20 | Alexander M Gold | Director | A | +6,200 | — |
| 2026-02-20 | RA Capital Nexus Fund III, L.P. | Director | A | +6,200 | — |
| 2026-02-20 | Brian Taylor Slingsby | Director | MIXED | +6,200 | — |
| 2026-02-17 | David Malcom Rodman | Chief Medical Officer | MIXED | — | −$5.07K |
| 2026-02-13 | David Malcom Rodman | Chief Medical Officer | MIXED | −6,348 | −$467.47K |
| 2026-02-11 | David Malcom Rodman | Chief Medical Officer | MIXED | — | −$30.85K |
| 2026-01-20 | David Malcom Rodman | Chief Medical Officer | MIXED | — | −$6.93K |
| 2026-01-15 | David Malcom Rodman | Chief Medical Officer | MIXED | −11,367 | −$527.61K |
| 2026-01-13 | Adam Scott Levy | CFO and Secretary | Sell | −10,758 | −$345.72K |
| 2026-01-13 | Jon Congleton | Chief Executive Officer | Sell | −16,236 | −$529.64K |
| 2026-01-13 | David Malcom Rodman | Chief Medical Officer | MIXED | — | −$235.76K |
| 2026-01-06 | David Malcom Rodman | Chief Medical Officer | MIXED | −10,031 | −$6.16M |
| 2025-11-24 | Jon Congleton | Chief Executive Officer | M | +24,082 | +$13.00K |
| 2025-11-21 | Brian Taylor Slingsby | Director | Sell | −1,000,000 | −$43.35M |
| 2025-11-13 | Jon Congleton | Chief Executive Officer | Sell | −200,000 | −$9.09M |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Brian Taylor Slingsby | Director | 7,805,718 | $125.40M |
| Srinivas Akkaraju | Director | 5,877,218 | $94.42M |
| Samsara BioCapital, L.P. | 10%+ Owner | 5,674,916 | $91.17M |
| RA Capital Nexus Fund III, L.P. | Director | 5,456,521 | $87.66M |
| RA Capital Healthcare Fund LP | Director | 1,867,229 | $30.00M |
| RA CAPITAL MANAGEMENT, L.P. | Director | 1,867,229 | $30.00M |
| Jon Congleton | Chief Executive Officer | 528,621 | $8.49M |
| James J. Ferguson III | Chief Medical Officer | 102,400 | $1.65M |
| David Malcom Rodman | Chief Medical Officer | 53,554 | $860.35K |
| Adam Scott Levy | CFO and Secretary | 48,538 | $779.76K |
| Eric Warren | Chief Commercial Officer | 38,400 | $616.90K |
| Kristine Peterson | Director | 12,400 | $199.21K |
| Lonnel Coats | Director | 12,400 | $199.21K |
| Daphne Karydas | Director | 9,200 | $147.80K |
| Alexander M Gold | Director | 6,200 | $99.60K |
| Derek DiRocco | Director | 6,200 | $99.60K |
| Glenn Sblendorio | Director | 6,200 | $99.60K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the MLYS quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.